RU2019100295A - Соединения и композиции для подавления активности shp2 - Google Patents
Соединения и композиции для подавления активности shp2 Download PDFInfo
- Publication number
- RU2019100295A RU2019100295A RU2019100295A RU2019100295A RU2019100295A RU 2019100295 A RU2019100295 A RU 2019100295A RU 2019100295 A RU2019100295 A RU 2019100295A RU 2019100295 A RU2019100295 A RU 2019100295A RU 2019100295 A RU2019100295 A RU 2019100295A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- decan
- azaspiro
- hydrogen
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 9
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title claims 3
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title claims 3
- 230000000694 effects Effects 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 22
- -1 2-oxa-8-azaspiro [4.5] decan-8-yl Chemical group 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims 1
- 206010029748 Noonan syndrome Diseases 0.000 claims 1
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Compounds Of Unknown Constitution (AREA)
Claims (65)
1. Соединение, выбранное из формул I и II:
в которых:
R1 выбирают из:
R2 и R3 вместе с атомом азота, к которому присоединены оба R2 и R3, образуют кольцо, выбранное из пиперидинила, пиперазинила, 2-окса-8-азаспиро[4.5]декан-8-ила, 8-азаспиро[4.5]декан-8-ила и пирролидинила; где указанные пирролидинил, пиперазинил, 2-окса-8-азаспиро[4.5]декан-8-ил, 8-азаспиро[4.5]декан-8-ил или пиперидинил не замещены или замещены 1-3 группами, независимо выбранными из аминогруппы, метила, этила, амино-метила, метил-аминогруппы, гидроксила, цианогруппы, фтор-метила, фтора и ((((5-метил-2-оксо-1,3-диоксол-4-ил)метокси)карбонил)амино)метила;
R4 выбран из гидроксила, C1-3алкоксигруппы и OC(O)C1-3алкила;
R5 выбран из Н и метила;
R6 выбран из водорода, метила и фенила;
R7 выбран из водорода, метила, этила, фенила и бензила;
R8 выбран из водорода и метила;
Y1 выбран из N и CH;
Y2 выбран из N и CH;
Y3 выбран из NН и CH2;
Y4 выбран из N и CH;
Y5 выбран из N и CH; или его фармацевтически приемлемая соль.
2. Соединение по п. 1, характеризующееся формулой II:
в которой:
R1 выбирают из:
R2 и R3 вместе с атомом азота, к которому присоединены оба R2 и R3, образуют кольцо, выбранное из пиперидинила, пиперазинила, 2-окса-8-азаспиро[4.5]декан-8-ила, 8-азаспиро[4.5]декан-8-ила и пирролидинила; где указанные пирролидинил, пиперазинил, 2-окса-8-азаспиро[4.5]декан-8-ил, 8-азаспиро[4.5]декан-8-ил или пиперидинил не замещены или замещены 1-3 группами, независимо выбранными из аминогруппы, метила, этила, амино-метила, метил-аминогруппы, гидроксила, цианогруппы, фтор-метила, фтора и ((((5-метил-2-оксо-1,3-диоксол-4-ил)метокси)карбонил)амино)метила;
R4 выбран из гидроксила;
R5 выбран из Н и метила;
R6 выбран из водорода, метила и фенила;
R7 выбран из водорода, метила, этила, фенила и бензила;
R8 выбран из водорода и метила;
Y1 выбран из N и CH;
Y2 выбран из N и CH;
Y3 выбран из NН и CH2;
Y4 выбран из N и CH;
Y5 выбран из N и CH; или его фармацевтически приемлемая соль.
3. Соединение по п. 2 или его фармацевтически приемлемая соль, в котором:
R1 выбирают из:
R4 выбран из гидроксила;
R5 выбран из Н и метила;
R6 выбран из водорода, метила и фенила;
R7 выбран из водорода, метила, этила, фенила и бензила;
R8 выбран из водорода и метила;
Y4 выбран из N и CH; и
Y5 выбран из N и CH.
4. Соединение по п. 3 или его фармацевтически приемлемая соль, выбранное из:
5. Соединение по п. 1, характеризующееся формулой I:
в котором:
R1 выбирают из:
R2 и R3 вместе с атомом азота, к которому присоединены оба R2 и R3, образуют кольцо, выбранное из пиперидинила, пиперазинила, 2-окса-8-азаспиро[4.5]декан-8-ила, 8-азаспиро[4.5]декан-8-ила и пирролидинила; где указанные пирролидинил, пиперазинил, 2-окса-8-азаспиро[4.5]декан-8-ил, 8-азаспиро[4.5]декан-8-ил или пиперидинил незамещены или замещены 1-3 группами, независимо выбранными из аминогруппы, метила, этила, амино-метила, метил-аминогруппы, гидроксила, цианогруппы, фтор-метила, фтора и ((((5-метил-2-оксо-1,3-диоксол-4-ил)метокси)карбонил)амино)метила;
R4 выбран из гидроксила;
R5 выбран из Н и метила;
R6 выбран из водорода, метила и фенила;
R7 выбран из водорода, метила, этила, фенила и бензила;
R8 выбран из водорода и метила;
Y1 выбран из N и CH;
Y2 выбран из N и CH;
Y3 выбран из NН и CH2;
Y4 выбран из N и CH;
Y5 выбран из N и CH; или его фармацевтически приемлемая соль.
6. Соединение по п. 5 или его фармацевтически приемлемая соль, выбранное из:
7. Фармацевтическая композиция, содержащая соединение по п. 1 или его фармацевтически приемлемую соль и по меньшей мере один фармацевтически приемлемый носитель.
8. Способ лечения, включающий в себя введение соединения по п. 1 или его фармацевтически приемлемой соли лицу, нуждающемуся в таком лечении, в эффективном количестве для профилактики или терапевтического лечения заболевания или расстройства, опосредованного активностью SHP2.
9. Способ по п. 8, где заболевание или расстройство, опосредованное активностью SHP2, выбрано из синдрома Нунан, синдрома Leopard, ювенильных миеломоноцитарных лейкозов, нейробластомы, меланомы, острого миелоидного лейкоза, рака молочной железы, рака пищевода, рака легкого, рака толстой кишки, рака головы, нейробластомы, плоскоклеточной карциномы головы и шеи, карциномы желудка, анапластической крупноклеточной лимфомы и глиобластомы.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662349697P | 2016-06-14 | 2016-06-14 | |
US62/349,697 | 2016-06-14 | ||
PCT/IB2017/053469 WO2017216706A1 (en) | 2016-06-14 | 2017-06-12 | Compounds and compositions for inhibiting the activity of shp2 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021106500A Division RU2021106500A (ru) | 2016-06-14 | 2017-06-12 | Соединения и композиции для подавления активности shp2 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019100295A3 RU2019100295A3 (ru) | 2020-07-14 |
RU2019100295A true RU2019100295A (ru) | 2020-07-14 |
RU2744988C2 RU2744988C2 (ru) | 2021-03-17 |
Family
ID=59215837
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021106500A RU2021106500A (ru) | 2016-06-14 | 2017-06-12 | Соединения и композиции для подавления активности shp2 |
RU2019100295A RU2744988C2 (ru) | 2016-06-14 | 2017-06-12 | Соединения и композиции для подавления активности shp2 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021106500A RU2021106500A (ru) | 2016-06-14 | 2017-06-12 | Соединения и композиции для подавления активности shp2 |
Country Status (14)
Country | Link |
---|---|
US (3) | US10934285B2 (ru) |
EP (1) | EP3468972B1 (ru) |
JP (2) | JP6994474B2 (ru) |
KR (1) | KR102457146B1 (ru) |
CN (2) | CN114057689A (ru) |
AU (1) | AU2017283769B2 (ru) |
CA (1) | CA3023216A1 (ru) |
EA (1) | EA036446B1 (ru) |
ES (1) | ES2810852T3 (ru) |
MX (2) | MX2018015625A (ru) |
PL (1) | PL3468972T3 (ru) |
PT (1) | PT3468972T (ru) |
RU (2) | RU2021106500A (ru) |
WO (1) | WO2017216706A1 (ru) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2017211303A1 (en) * | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
IL311645A (en) | 2016-07-12 | 2024-05-01 | Revolution Medicines Inc | 2,5-dimethomers of 3-methylpyrazines and 2,5,6-dimethomers of 3-methylpyrazines as allosteric SHP2 inhibitors |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
WO2018081091A1 (en) | 2016-10-24 | 2018-05-03 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
KR102571130B1 (ko) | 2017-01-10 | 2023-08-28 | 노파르티스 아게 | Alk 저해제 및 shp2 저해제를 포함하는 약제학적 조합 |
MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
JP7356414B2 (ja) | 2017-09-07 | 2023-10-04 | レヴォリューション・メディスンズ,インコーポレイテッド | がんを治療するためのshp2阻害剤組成物および方法 |
CN111201223B (zh) | 2017-09-11 | 2024-07-09 | 克鲁松制药公司 | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 |
WO2019067843A1 (en) | 2017-09-29 | 2019-04-04 | Relay Therapeutics, Inc. | PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2 |
JP2020536881A (ja) * | 2017-10-12 | 2020-12-17 | レヴォリューション・メディスンズ,インコーポレイテッド | アロステリックshp2阻害剤としてのピリジン、ピラジンおよびトリアジン化合物 |
CN111433205B (zh) | 2017-12-15 | 2024-01-19 | 锐新医药公司 | 作为变构shp2抑制剂的多环化合物 |
JP7335882B2 (ja) | 2018-02-13 | 2023-08-30 | ブルーレイ セラピューティクス (シャンハイ) カンパニー,リミティド | ピリミジン縮合環式化合物及びその製造方法、並びに使用 |
CN111902415A (zh) | 2018-03-02 | 2020-11-06 | 大冢制药株式会社 | 药学化合物 |
TW201940167A (zh) | 2018-03-21 | 2019-10-16 | 美商新標利亞治療藥物公司 | Shp2抑制劑及其用途 |
TW202003471A (zh) | 2018-03-21 | 2020-01-16 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
WO2019213318A1 (en) | 2018-05-02 | 2019-11-07 | Board Of Regents, The University Of Texas System | Substituted heterocyclic inhibitors of ptpn11 |
WO2020022323A1 (en) | 2018-07-24 | 2020-01-30 | Taiho Pharmaceutical Co., Ltd. | Heterobicyclic compounds for inhibiting the activity of shp2 |
JP2021534124A (ja) | 2018-08-10 | 2021-12-09 | ナビール ファーマ,インコーポレイティド | 癌治療用ptpn11(shp2)阻害剤としての6−(4−アミノ−3−メチル−2−オキサ−8−アザスピロ[4.5]デカン−8−イル)−3−(2,3−ジクロロフェニル)−2−メチルピリミジン−4(3h)−オン誘導体及び関連化合物 |
SG11202102679QA (en) | 2018-09-18 | 2021-04-29 | Nikang Therapeutics Inc | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
IL281726B2 (en) | 2018-09-29 | 2024-03-01 | Novartis Ag | Production of compounds and preparations to inhibit the activity of SHP2 |
EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
BR112021005733A2 (pt) | 2018-10-17 | 2021-07-27 | Array Biopharma Inc. | inibidores de proteína tirosina fosfatase |
CN117143079A (zh) | 2018-11-06 | 2023-12-01 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
CN111333663A (zh) * | 2018-12-19 | 2020-06-26 | 天津医科大学 | 一类环烷基并噻吩并嘧啶酮化合物及其制法和用途 |
CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药(苏州)有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
AU2020232026A1 (en) | 2019-03-07 | 2021-09-02 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as shp2 antagonists |
CR20210501A (es) | 2019-04-02 | 2021-11-02 | Array Biopharma Inc | Inhibidores de la proteína tirosina fosfatasa |
CA3127475A1 (en) | 2019-04-08 | 2020-10-15 | Merck Patent Gmbh | Pyrimidinone derivatives as shp2 antagonists |
EP3772513A1 (en) * | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
CN114502165A (zh) * | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
AU2020354475A1 (en) | 2019-09-24 | 2022-05-05 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of making and using the same |
TW202136276A (zh) | 2019-12-20 | 2021-10-01 | 美商艾瑞斯卡公司 | 三環吡啶酮及嘧啶酮 |
US20230348467A1 (en) | 2020-01-16 | 2023-11-02 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof |
CN113754683A (zh) | 2020-06-05 | 2021-12-07 | 上海奕拓医药科技有限责任公司 | 同位素取代的螺芳环化合物及其应用 |
CN115734966A (zh) * | 2020-06-12 | 2023-03-03 | 石药集团中奇制药技术(石家庄)有限公司 | 杂环化合物及其用途 |
BR112022025550A2 (pt) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras |
WO2021259077A1 (zh) * | 2020-06-22 | 2021-12-30 | 四川科伦博泰生物医药股份有限公司 | 取代吡嗪类化合物,包含其的药物组合物及其用途 |
CN114053270B (zh) * | 2020-08-05 | 2023-06-13 | 兰州大学第二医院 | 泛素结合酶e2t的小分子抑制剂 |
CN111943988B (zh) * | 2020-08-17 | 2023-04-18 | 奥来德(上海)光电材料科技有限公司 | 一种铱掺杂电致发光材料及其制备方法和光电器件 |
CN114195799A (zh) * | 2020-09-02 | 2022-03-18 | 勤浩医药(苏州)有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
TW202227460A (zh) | 2020-09-15 | 2022-07-16 | 美商銳新醫藥公司 | Ras抑制劑 |
KR20230094198A (ko) | 2020-09-23 | 2023-06-27 | 에라스카, 아이엔씨. | 3환식 피리돈 및 피리미돈 |
WO2022089389A1 (zh) * | 2020-10-30 | 2022-05-05 | 赣江新区博瑞创新医药有限公司 | 杂环化合物及其制备方法、药物组合物和应用 |
CN112062699B (zh) * | 2020-11-13 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种邻氨基苯硫酚的制备方法 |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
EP4039685A1 (en) | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
EP4067358A1 (en) | 2021-04-02 | 2022-10-05 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer |
TW202309053A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ras抑制劑 |
AU2022271244A1 (en) * | 2021-05-05 | 2023-12-07 | Huyabio International, Llc | Shp2 inhibitor monotherapy and uses thereof |
EP4334318A1 (en) * | 2021-05-05 | 2024-03-13 | Huyabio International, LLC | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
JP2024516998A (ja) * | 2021-05-05 | 2024-04-18 | フヤバイオ インターナショナル,エルエルシー | Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法 |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
CR20230570A (es) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Inhibidores de ras |
CN115340561A (zh) * | 2021-05-14 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶稠环类抑制剂的制备及其应用 |
CN115340559A (zh) * | 2021-05-12 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶杂环类抑制剂的制备及其应用 |
WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
WO2022266473A1 (en) * | 2021-06-17 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Small molecule disruptors of protein interactions in histone deacetylase complexes |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
CN117881678A (zh) * | 2021-08-09 | 2024-04-12 | 尤比克斯治疗公司 | 具有shp2蛋白降解活性的化合物及其医学用途 |
CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
CN113717178B (zh) * | 2021-09-30 | 2022-07-22 | 上海皓鸿生物医药科技有限公司 | 一种shp2抑制剂的中间体及其制备方法 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
CN118401505A (zh) * | 2021-12-28 | 2024-07-26 | 捷思英达控股有限公司 | 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物及其使用方法 |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek抑制劑及其用途 |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
EP4345101A1 (en) | 2022-09-29 | 2024-04-03 | Irbm S.P.A. | Azole derivatives as shp2 inhibitors |
WO2024085699A1 (ko) * | 2022-10-19 | 2024-04-25 | 주식회사 유빅스테라퓨틱스 | Shp2 단백질 분해용 화합물 및 이들의 의약 용도 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体 |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US4512991A (en) | 1982-12-27 | 1985-04-23 | Merck & Co., Inc. | 3-Acyl-2-amino-5-halo-6-(substituted)pyrazine antimicrobial compounds |
FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
WO1987004928A1 (en) | 1986-02-24 | 1987-08-27 | Mitsui Petrochemical Industries, Ltd. | Agents for treating neurophathy |
US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
DK169008B1 (da) | 1990-06-01 | 1994-07-25 | Holec Lk A S | Fremgangsmåde og skærm til afskærmning af en strømtransformer samt strømtransformer med en sådan afskærmning |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
MA26473A1 (fr) | 1997-03-01 | 2004-12-20 | Glaxo Group Ltd | Composes pharmacologiquement actifs. |
WO2000059893A1 (en) | 1999-04-06 | 2000-10-12 | Krenitsky Pharmaceuticals Inc. | Neurotrophic thio substituted pyrimidines |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
CA2463989C (en) | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
EA008379B1 (ru) | 2002-02-01 | 2007-04-27 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их применения |
US20040034037A1 (en) | 2002-02-06 | 2004-02-19 | Harbeson Scott L. | Heteroaryl compounds useful as inhibitors of GSK-3 |
PL215865B1 (pl) | 2002-03-05 | 2014-02-28 | Axys Pharmaceuticals | Zwiazek, kompozycja farmaceutyczna i zastosowanie zwiazku |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
GB0300783D0 (en) | 2003-01-14 | 2003-02-12 | Btg Int Ltd | Treatment of neurodegenerative conditions |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
CN1938296A (zh) | 2004-04-01 | 2007-03-28 | 安斯泰来制药有限公司 | 作为腺苷拮抗剂的吡嗪衍生物及其制药用途 |
CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
KR20130083488A (ko) | 2004-09-02 | 2013-07-22 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
EP1831168B1 (en) | 2004-12-16 | 2014-07-02 | Vertex Pharmaceuticals Inc. | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases. |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
BRPI0615880A2 (pt) | 2005-09-13 | 2011-05-31 | Palau Pharma Sa | compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica |
EP1999108A1 (en) | 2006-03-28 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
US7515405B2 (en) | 2006-07-25 | 2009-04-07 | Hewlett-Packard Development Company, L.P. | Anti-rotation mechanism for an electronic device |
WO2008055959A1 (en) | 2006-11-09 | 2008-05-15 | Galapagos N.V. | Novel compounds useful for the treatment of degenerative & inflammatory diseases |
EP2120573A4 (en) | 2007-02-12 | 2011-05-25 | Merck Sharp & Dohme | DERIVATIVES OF PIPERIDINE |
MY156814A (en) | 2007-03-15 | 2016-03-31 | Novartis Ag | Organic compounds and their uses |
TWI471134B (zh) | 2007-09-12 | 2015-02-01 | Genentech Inc | 肌醇磷脂3-激酶抑制劑化合物及化療劑之組合及使用方法 |
EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP2011522865A (ja) | 2008-06-13 | 2011-08-04 | ノバルティス アーゲー | Ia心不全および癌の治療に有用なプロテインキナーゼd阻害剤としての2,4’−ビピリジニル化合物 |
JP2011524917A (ja) | 2008-06-20 | 2011-09-08 | メタボレックス, インコーポレイテッド | アリールgpr119作動薬およびその使用 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010067987A2 (ko) | 2008-12-10 | 2010-06-17 | 동화약품주식회사 | 신규한 2, 6-위치에 치환된 3-니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물 |
FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
EP3205647B1 (en) | 2009-08-17 | 2020-05-13 | Memorial Sloan-Kettering Cancer Center | 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders |
US8673913B2 (en) | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
BR112012033770A2 (pt) | 2010-06-30 | 2016-11-22 | Fujifilm Corp | novo derivado de nicotinamida ou sal do mesmo |
JP2013531037A (ja) | 2010-07-13 | 2013-08-01 | メルク・シャープ・エンド・ドーム・コーポレイション | スピロ環式化合物 |
MX338707B (es) | 2010-07-29 | 2016-04-28 | Rigel Pharmaceuticals Inc | Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos. |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
ES2543151T3 (es) | 2010-10-20 | 2015-08-17 | Pfizer Inc | Derivados de 2-piridina como moduladores del receptor Smoothened |
SG191129A1 (en) | 2010-12-13 | 2013-07-31 | Array Biopharma Inc | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
SI2755958T1 (sl) | 2011-09-12 | 2017-12-29 | Merck Patent Gmbh | Aminopirimidinski derivati za uporabo kot modulatorji kinazne aktivnosti |
WO2013096093A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Compounds as dgat-1 inhibitors |
BR112014030410A2 (pt) | 2012-06-07 | 2017-06-27 | Hoffmann La Roche | inibidores de pirazolopirimidona e pirazolopiridona de tanquirase |
CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
US9550793B2 (en) | 2012-10-03 | 2017-01-24 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
US10189859B2 (en) | 2013-12-21 | 2019-01-29 | Nektar Therapeutics | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
JP6473457B2 (ja) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物 |
WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
US9255097B2 (en) | 2014-05-01 | 2016-02-09 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
US10174032B2 (en) | 2014-05-05 | 2019-01-08 | Signalrx Pharmaceuticals, Inc. | Heterocyclic compound classes for signaling modulation |
WO2016023404A1 (zh) | 2014-08-15 | 2016-02-18 | 贵州省中国科学院天然产物化学重点实验室 | 双苄基异喹啉衍生物、其制备方法及其在肝病的治疗与预防中的用途 |
ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
ES2805232T3 (es) | 2015-06-19 | 2021-02-11 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2017211303A1 (en) * | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
IL311645A (en) | 2016-07-12 | 2024-05-01 | Revolution Medicines Inc | 2,5-dimethomers of 3-methylpyrazines and 2,5,6-dimethomers of 3-methylpyrazines as allosteric SHP2 inhibitors |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
WO2018081091A1 (en) | 2016-10-24 | 2018-05-03 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
KR102571130B1 (ko) | 2017-01-10 | 2023-08-28 | 노파르티스 아게 | Alk 저해제 및 shp2 저해제를 포함하는 약제학적 조합 |
CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
JP7356414B2 (ja) | 2017-09-07 | 2023-10-04 | レヴォリューション・メディスンズ,インコーポレイテッド | がんを治療するためのshp2阻害剤組成物および方法 |
WO2019067843A1 (en) | 2017-09-29 | 2019-04-04 | Relay Therapeutics, Inc. | PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2 |
JP2020536881A (ja) | 2017-10-12 | 2020-12-17 | レヴォリューション・メディスンズ,インコーポレイテッド | アロステリックshp2阻害剤としてのピリジン、ピラジンおよびトリアジン化合物 |
CN111433205B (zh) | 2017-12-15 | 2024-01-19 | 锐新医药公司 | 作为变构shp2抑制剂的多环化合物 |
WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW202003471A (zh) | 2018-03-21 | 2020-01-16 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
SG11202009793TA (en) | 2018-04-10 | 2020-10-29 | Revolution Medicines Inc | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
-
2017
- 2017-06-12 KR KR1020197001042A patent/KR102457146B1/ko active IP Right Grant
- 2017-06-12 EA EA201990019A patent/EA036446B1/ru not_active IP Right Cessation
- 2017-06-12 EP EP17733041.2A patent/EP3468972B1/en active Active
- 2017-06-12 PT PT177330412T patent/PT3468972T/pt unknown
- 2017-06-12 MX MX2018015625A patent/MX2018015625A/es unknown
- 2017-06-12 RU RU2021106500A patent/RU2021106500A/ru unknown
- 2017-06-12 PL PL17733041T patent/PL3468972T3/pl unknown
- 2017-06-12 CN CN202111269841.9A patent/CN114057689A/zh active Pending
- 2017-06-12 ES ES17733041T patent/ES2810852T3/es active Active
- 2017-06-12 JP JP2018564910A patent/JP6994474B2/ja active Active
- 2017-06-12 CA CA3023216A patent/CA3023216A1/en active Pending
- 2017-06-12 RU RU2019100295A patent/RU2744988C2/ru active
- 2017-06-12 US US16/309,076 patent/US10934285B2/en active Active
- 2017-06-12 WO PCT/IB2017/053469 patent/WO2017216706A1/en active Application Filing
- 2017-06-12 AU AU2017283769A patent/AU2017283769B2/en active Active
- 2017-06-12 CN CN201780036798.7A patent/CN109415360B/zh active Active
-
2018
- 2018-12-13 MX MX2021007432A patent/MX2021007432A/es unknown
-
2020
- 2020-12-22 US US17/130,374 patent/US11905283B2/en active Active
-
2021
- 2021-12-13 JP JP2021201383A patent/JP7278359B2/ja active Active
-
2023
- 2023-11-29 US US18/523,565 patent/US20240199609A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017216706A1 (en) | 2017-12-21 |
RU2744988C2 (ru) | 2021-03-17 |
PL3468972T3 (pl) | 2020-11-16 |
CN109415360A (zh) | 2019-03-01 |
EA201990019A1 (ru) | 2019-05-31 |
KR102457146B1 (ko) | 2022-10-19 |
EP3468972B1 (en) | 2020-05-20 |
JP7278359B2 (ja) | 2023-05-19 |
KR20190017960A (ko) | 2019-02-20 |
CA3023216A1 (en) | 2017-12-21 |
RU2021106500A3 (ru) | 2021-08-13 |
EA036446B1 (ru) | 2020-11-11 |
US20210300919A1 (en) | 2021-09-30 |
JP6994474B2 (ja) | 2022-01-14 |
JP2022037083A (ja) | 2022-03-08 |
BR112018075663A2 (pt) | 2019-04-09 |
US11905283B2 (en) | 2024-02-20 |
ES2810852T3 (es) | 2021-03-09 |
AU2017283769B2 (en) | 2019-08-15 |
US20240199609A1 (en) | 2024-06-20 |
JP2019518033A (ja) | 2019-06-27 |
PT3468972T (pt) | 2020-08-21 |
RU2019100295A3 (ru) | 2020-07-14 |
US20200002330A1 (en) | 2020-01-02 |
MX2021007432A (es) | 2021-08-05 |
EP3468972A1 (en) | 2019-04-17 |
MX2018015625A (es) | 2019-03-06 |
CN109415360B (zh) | 2021-11-02 |
CN114057689A (zh) | 2022-02-18 |
US10934285B2 (en) | 2021-03-02 |
AU2017283769A1 (en) | 2019-01-31 |
RU2021106500A (ru) | 2021-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2019100295A (ru) | Соединения и композиции для подавления активности shp2 | |
JP2017503000A5 (ru) | ||
JP2020530838A5 (ru) | ||
RU2019122598A (ru) | Циклические динуклеотидные агонисты sting для лечения рака | |
RU2019131111A (ru) | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ | |
RU2017103757A (ru) | Аминопиридазиноновые соединения в качестве ингибиторов протеинкиназы | |
RU2016140420A (ru) | Производное 1,3-бензодиоксола | |
JP2018507877A5 (ru) | ||
JP2015533177A5 (ru) | ||
FI3810602T3 (fi) | Yhdisteitä | |
JP2008506761A5 (ru) | ||
RU2018107668A (ru) | Пиразолпиримидиновое производное и его применение | |
RU2012108629A (ru) | Фенилэтинильные производные в качестве ингибиторов вируса гепатита с | |
JP2014534200A5 (ru) | ||
JP2014513101A5 (ru) | ||
RU92004336A (ru) | Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты | |
RU2008120408A (ru) | Соединения, связывающие bir домены iap | |
RU2008111991A (ru) | Органические соединения | |
EP4048270A1 (en) | Pharmaceutical combination of prmt5 inhibitors | |
RU2343145C2 (ru) | Производные изоиндолина | |
JP2010538003A5 (ru) | ||
RU2012139033A (ru) | Bir домен iap связывающие соединения | |
HRP20090565T1 (hr) | Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
RU2008106949A (ru) | Бензимидазолы применимые в качестве ингибиторов протеинкиназ | |
JP2018507887A5 (ru) |